Abstracts tagged "phenotypes and rheumatoid arthritis (RA)"

Abstract Number: 342 • 2018 ACR/ARHP Annual Meeting
Optimizing the Dataset to Collect from Patients to Accurately Predict Their Status Prior to the Clinic Visit
Eric Newman¹, Elizabeth Thomas², Andrea Berger³ and H. Lester Kirchner³, ¹Department of Rheumatology, Geisinger Medical Center, Danville, PA, ²Rheumatology, Geisinger Medical Center, Danville, PA, ³Geisinger Medical Center, Danville, PA
Background/Purpose: Understanding a patient’s status before entering the exam room, or accurately tracking status between visits, is vital to creating more efficient ways to apply…
Abstract Number: 587 • 2016 ACR/ARHP Annual Meeting
Synovial Immunophenotype and Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiological Prognosis
Carl Orr¹, Aurélie Najm², Monika Biniecka³, Francis Young¹, Ursula Fearon⁴ and Douglas J. Veale¹, ¹Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ²Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, ³St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, ⁴Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland
Background/Purpose: Circulating anti-citrullinated peptide antibodies (ACPA) have been proposed as an important clinical test for stratification of patients presenting with rheumatoid arthritis (RA). ACPA may…
Abstract Number: 1217 • 2015 ACR/ARHP Annual Meeting
Phenome-Wide Association Study of Novel Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis
Katherine Liao¹, Jeffrey A. Sparks¹, Boris Hejblum², I-Hsin Kuo¹, Jing Cui¹, Lauren J. Lahey³, Andrew Cagan⁴, Vivian Gainer⁴, Weidong Liu⁵, Tony Cai⁶, Jeremy Sokolove⁷ and Tianxi Cai², ¹Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ²Biostatistics, Harvard School of Public Health, Boston, MA, ³Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ⁴Research Computing, Partners HealthCare, Charlestown, MA, ⁵Institute of Natural Sciences, Shanghai Jiao Tong University, Shanghai, China, ⁶Statistics, University of Pennsylvania, Philadelphia, PA, ⁷Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA
Background/Purpose: RA patients develop autoantibodies against a spectrum of antigens. However, the clinical significance of these autoantibodies after RA diagnosis is unclear. The Phenome-Wide Association…
Abstract Number: 1541 • 2015 ACR/ARHP Annual Meeting
Subgroups of Established Rheumatoid Arthritis Patients Can be Characterized By Patient and Physician Assessment Discrepancy, Anxiety and Depression and Presence of Depression Might be Associated with Slower Response to Treatment
Yong Gil Hwang¹, Juan (June) Feng², Heather Eng², Jason Lyons², Anthony Fabio³ and Larry W. Moreland⁴, ¹Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Department Of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) is a heterogeneous inflammatory disease with various signs and symptoms. Previous studies have shown that RA patients can be sub-grouped based…
Abstract Number: 2592 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients with Many Autoantibodies Have Different Characteristics at Presentation Compared to Patients with Few Autoantibodies
Veerle F.A.M. Derksen¹, Sofia Ajeganova², Annette H.M. van der Helm- van Mil¹, Ingiäld Hafström³, T. W. J. Huizinga¹, René E. M. Toes¹, Leendert A. Trouw¹, Björn Svensson⁴ and Diane van der Woude¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology unit, Department of Medicine,, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden, ³Unit of Rheumatology, Department of Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden, ⁴Section of Rheumatology, Institution of Clinical Science, Lund University, Lund, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) are frequently positive for one or several autoantibodies like rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and anti-carbamylated protein…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].